Summary of Investments Made

$71.7M
Total to date

By Funding Area – In $Millions

$21.8
Discovery
$39.9
Clinical
$0.6
Manufacturing
$0
Introduction and Delivery
$9.4
Real World Evidence and Data Platforms
$0
Diagnostics

Clinical Investments

Filter Investments:
Sort by:
Use Case
Title
Description

Use Case: Pre-exposure Prophylaxis

Title: Henry Ford Health System WHIP Trial

Description:

Started early April in Michigan and Ohio and will target 3,000 health workers and first responders using hydroxychloroquine as pre-exposure prophylaxis. Currently at ~20% enrollment. This trial is expanding nationally to Texas, Arizona, and Florida and internationally to Brazil, Peru, Ecuador and Mexico. 

Use Case: Pre-exposure Prophylaxis

Title: University of Oxford / Mahidol Oxford Tropical Medicine Research Unit (MORU) COPCOV Trial

Description:

Began at the end of March and uses hydroxychloroquine and chloroquine as pre-exposure prophylaxis. This will target 40,000 health workers, hospital inpatients and inpatient relatives who may become exposed to COVID-19.

Use Case: Pre-exposure Prophylaxis

Title: Washington University of St. Louis CROWN CORONATION Trial

Description:

The study began in September 2020 and seeks to include up to 30,000 health workers globally to determine the efficacy of the MR/MMR vaccine as pre-exposure prophylaxis. 

Use Case: Post-exposure Prophylaxis

Title: University of Washington: Post-exposure Prophylaxis Using Hydroxychloroquine

Description:

Aimed to test the efficacy of HCQ to prevent incidence of SARS-CoV-2 infection. The study has been completed.

Use Case: Prophylaxis

Title: Prophylaxis Registry Trial in Low and Middle-income Countries

Description:

Seeks to collect real-world evidence by capturing health workers’ self-initiated prophylaxis treatments and outcomes. The goal is to cover 10,000 health workers in six low- and middle-income country (LMIC) sites. Regulatory approval has been granted in Pakistan, and data collection started in early August.  

Use Case: Mild Disease Treatment

Title: Medicines for Malaria Ventures ReACT trial

Description:

Exploratory study to be conducted in South Africa using five different experimental treatment arms versus standard of care for the treatment of COVID-19 infection in symptomatic outpatients with mild disease at the time of enrollment. 

Use Case: Mild Disease Treatment

Title: Montreal Heart Institute COLCORONA Trial: Mild Disease Treatment Using Colchicine

Description:

Started in March in Quebec and has since expanded to Spain, New York and California. This trial is targeting 6,000 outpatients using Colchicine to treat mild COVID-19. Given positive interim read-outs in June, this trial will continue to expand. ~25% enrollment completed.  

Use Case: Mild Disease Treatment

Title: University of Washington high risk outpatient trial

Description:

Targets high-risk patients in the outpatient setting initially using hydroxychloroquine (HCQ), HCQ + azithromycin (AZ), and Kaletra to treat mild COVID-19. HCQ and HCQ+AZ arms were discontinued in late July and the study is moving forward with Kaletra.  

Use Case: Moderate Disease Treatment

Title: University of Minnesota inpatient study

Description:

Includes a small group of 220 patients early in hospitalization in Cincinnati, Minnesota and Gainsville. This trial started at the end of April and is using Losartan to treat moderate COVID-19 and prevent progression. Expanding recruitment to 10 sites, this trial has achieved ~40% enrollment thus far.